Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

Anja Hviid Simonsen, Sanna-Kaisa Herukka, Niels Andreasen, Ines Baldeiras, Maria Bjerke, Kaj Blennow, Sebastiaan Engelborghs, Giovanni B. Frisoni, Tomasz Gabryelewicz, Samantha Galluzzi, Ron Handels, Milica G. Kramberger, Agnieszka Kulczynska, Jose Luis Molinuevo, Barbara Mroczko, Agneta Nordberg, Catarina Resende Oliveira, Markus Otto, Juha O. Rinne, Uros RotEsen Saka, Hilkka Soininen, Hanne Struyfs, Silvia Suardi, Pieter Jelle Visser, Bengt Winblad, Henrik Zetterberg, Gunhild Waldemar*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

84 Citations (Web of Science)

Abstract

This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebiospinal fluid (CSF) amyloid-beta(1-42), tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support 4 recommendation to use CSF ADbiomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD bioniarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.

Original languageEnglish
Pages (from-to)274-284
Number of pages11
JournalAlzheimer's & Dementia
Volume13
Issue number3
DOIs
Publication statusPublished - Mar 2017

Keywords

  • Alzheiiner's disease
  • Biomarkers
  • CSF
  • Diagnosis
  • GRADE
  • Recommendations
  • ALZHEIMERS-DISEASE DIAGNOSIS
  • MILD COGNITIVE IMPAIRMENT
  • CEREBROSPINAL-FLUID TAU
  • COST-EFFECTIVENESS
  • PHOSPHORYLATED TAU
  • GRADING QUALITY
  • METAANALYSIS
  • GUIDELINES
  • MANAGEMENT
  • CRITERIA

Cite this